Gilead Sciences Inc. (GILD) News
Filter GILD News Items
GILD News Results
|Loading, please wait...
GILD News Highlights
- GILD's 30 day story count now stands at 22.
- Over the past 20 days, the trend for GILD's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- DRUG, PRE and CE are the most mentioned tickers in articles about GILD.
Latest GILD News From Around the Web
Below are the latest news stories about GILEAD SCIENCES INC that investors may wish to consider to help them evaluate GILD as an investment opportunity.
These are the very best stocks to buy for 2024 for any investor, according to Tom Yeung's MarketMasterAI system.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
In this article, we will take a look at the 30 happiest cities in America in 2023. If you want to skip our discussion on the impact of residence on well-being, you can go directly to The 5 Happiest Cities in America in 2023. Despite the common belief that money can’t buy happiness, one cannot deny […]
In this article, we discuss the 12 best stocks to buy for an 18 year old. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Stocks to Buy for an 18 Year Old. It is an exciting time to be involved in trading stocks. The Federal Reserve in […]
In pharma, a company can take a larger slice of the healthcare pie than peers, but it is still constrained by the size of the pie.
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Hookipa Pharma stock is rising higher on Thursday as investors react to a purchase agreement for 15 million shares of HOOK.
It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone."
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data
SANTA MONICA, Calif., December 21, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta® (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study showing a statistically significant improvement for Yescarta in OS versus standard of care (SOC) as second-line treatment with curative intent for patients with relapsed or refractory large B-ce
FOSTER CITY, Calif., December 21, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: